Diamyd Medical secures precision medicine patent for prevention and treatment of autoimmune diabetes

The European Patent Office has informed Diamyd Medical that the Company’s patent application regarding prevention and treatment of autoimmune diabetes in individuals carrying the HLA DR3-DQ2 gene will be granted. The patent is valid until 2035 and provides central protection in Europe for the treatment or prevention of genetically defined autoimumune diabetes using GAD, which is the active component in the therapeutic diabetes vaccine Diamyd[®]. The patent claims cover the patient population in which Diamyd[®] has shown efficacy and is targeted in the upcoming Phase III trial DIAGNODE-3.“